Tetsuo Kume1,2, Rika Shimizu3, Kana Akiyama4, Takayuki Tsuchiya4, Michihiro Shino4, Takashi Ikeda5, Shinichi Iwai6. 1. Department of Healthcare and Regulatory Sciences, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. t.kume@scchr.jp. 2. Department of Pharmacy, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. t.kume@scchr.jp. 3. Department of Nursing, Shizuoka Cancer Center, Shizuoka, Japan. 4. Department of Pharmacy, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. 5. Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan. 6. Department of Healthcare and Regulatory Sciences, Showa University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Abstract
PURPOSE: Hand-foot syndrome (HFS) is a typical skin disorder caused by the use of cytotoxic anticancer drugs and molecular targets. Similarly, various anticancer drugs have been used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT), and skin disorders such as HFS have been reported. The aim of this study was to determine retrospectively the frequency of HFS in recipients who have received a first allogeneic HSCT and the risk factors for HFS occurrence. METHODS: We retrospectively investigated the medical records of recipients who received their first allogeneic HSCT and neutrophil engraftment at Shizuoka Cancer Center from January 1, 2011, to December 31, 2019. RESULTS: The occurrence of HFS was confirmed in 78 cases (48.1%), and no grade 3 HFS was confirmed. The median occurrence of HFS was 8 (- 3 to 19) days. In recipients with and without confirmed HFS, the median neutrophil engraftment day was 16.5 (10-33) and 15.0 (11-26) days, respectively (p = 0.013). Multivariate analysis indicated that the frequency of HFS was statistically significantly higher in women (p = 0.032), recipients administered busulfan (Bu) four times daily (p = 0.011), and recipients previously treated with anthracycline (p = 0.002). CONCLUSION: Attention should be paid to HFS that occurs due to the conditioning regimen for HSCT in women, recipients who received 0.8 mg/kg of Bu four times a day, and recipients with a history of anthracycline administration, as HFS may affect the duration to neutrophil engraftment.
PURPOSE: Hand-foot syndrome (HFS) is a typical skin disorder caused by the use of cytotoxic anticancer drugs and molecular targets. Similarly, various anticancer drugs have been used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT), and skin disorders such as HFS have been reported. The aim of this study was to determine retrospectively the frequency of HFS in recipients who have received a first allogeneic HSCT and the risk factors for HFS occurrence. METHODS: We retrospectively investigated the medical records of recipients who received their first allogeneic HSCT and neutrophil engraftment at Shizuoka Cancer Center from January 1, 2011, to December 31, 2019. RESULTS: The occurrence of HFS was confirmed in 78 cases (48.1%), and no grade 3 HFS was confirmed. The median occurrence of HFS was 8 (- 3 to 19) days. In recipients with and without confirmed HFS, the median neutrophil engraftment day was 16.5 (10-33) and 15.0 (11-26) days, respectively (p = 0.013). Multivariate analysis indicated that the frequency of HFS was statistically significantly higher in women (p = 0.032), recipients administered busulfan (Bu) four times daily (p = 0.011), and recipients previously treated with anthracycline (p = 0.002). CONCLUSION: Attention should be paid to HFS that occurs due to the conditioning regimen for HSCT in women, recipients who received 0.8 mg/kg of Bu four times a day, and recipients with a history of anthracycline administration, as HFS may affect the duration to neutrophil engraftment.
Authors: Yoon-Koo Kang; Sung Sook Lee; Dok Hyun Yoon; So Young Lee; Young Ju Chun; Min Sun Kim; Min-Hee Ryu; Heung-Moon Chang; Jae-Lyun Lee; Tae Won Kim Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: Brian I Rini; Bernard Escudier; Piotr Tomczak; Andrey Kaprin; Cezary Szczylik; Thomas E Hutson; M Dror Michaelson; Vera A Gorbunova; Martin E Gore; Igor G Rusakov; Sylvie Negrier; Yen-Chuan Ou; Daniel Castellano; Ho Yeong Lim; Hirotsugu Uemura; Jamal Tarazi; David Cella; Connie Chen; Brad Rosbrook; Sinil Kim; Robert J Motzer Journal: Lancet Date: 2011-11-04 Impact factor: 79.321
Authors: A Poprach; T Pavlik; B Melichar; I Puzanov; L Dusek; Z Bortlicek; R Vyzula; J Abrahamova; T Buchler Journal: Ann Oncol Date: 2012-06-13 Impact factor: 32.976
Authors: D Yamamoto; S Iwase; H Yoshida; Y Kuroda; C Yamamoto; K Kitamura; H Odagiri; Y Nagumo Journal: Anticancer Res Date: 2010-09 Impact factor: 2.480
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: David G Mutch; Mauro Orlando; Tiana Goss; Michael G Teneriello; Alan N Gordon; Scott D McMeekin; Yanping Wang; Dennis R Scribner; Martin Marciniack; R Wendel Naumann; Angeles Alvarez Secord Journal: J Clin Oncol Date: 2007-07-01 Impact factor: 44.544